AASraw
AASraw aims to be the most trusted CDMO of API !
- Oct 22, 2017
- 284
- 39
Anxiety disorders are among the most common mental health conditions worldwide, affecting hundreds of millions of people. Current treatment options—including selective serotonin reuptake inhibitors (SSRIs) and benzodiazepines—are often limited by side effects, delayed onset of action, and dependency issues. Amid this unmet need, BNC210 has emerged as a potentially transformative therapy in the field of neuropsychiatry.
Clinical Trials and Results
Bionomics has completed multiple Phase I and II clinical trials for BNC210, primarily focusing on generalized anxiety disorder and PTSD. While some early trials produced mixed results, a reformulated version of BNC210 (optimized for oral bioavailability and longer half-life) has shown promising pharmacokinetic properties and potential efficacy.
Notably, in a 2021 Phase IIb trial for PTSD, BNC210 demonstrated clinically meaningful improvements in PTSD symptoms, including reductions in anxiety, hypervigilance, and sleep disturbances. The FDA has granted Fast Track designation for BNC210 in PTSD, underscoring its potential to address a significant unmet medical need.
Clinical Trials and Results
Bionomics has completed multiple Phase I and II clinical trials for BNC210, primarily focusing on generalized anxiety disorder and PTSD. While some early trials produced mixed results, a reformulated version of BNC210 (optimized for oral bioavailability and longer half-life) has shown promising pharmacokinetic properties and potential efficacy.
Notably, in a 2021 Phase IIb trial for PTSD, BNC210 demonstrated clinically meaningful improvements in PTSD symptoms, including reductions in anxiety, hypervigilance, and sleep disturbances. The FDA has granted Fast Track designation for BNC210 in PTSD, underscoring its potential to address a significant unmet medical need.
